Table 1.
Report | Age/sex | Cadaver/living | Diffuse/focal | Diagnosis after RTx (m) | TG/VR/DSA | ABMR | Medication | Outcome |
---|---|---|---|---|---|---|---|---|
Chikamoto et al. [5] | 16/F | Living | Diffuse | 20 | −/+/− | − | mPSL, OKT3, DSG | Graft loss |
Suzuki et al. [6] | 59/M | Cadaver | Unknown | 36 | −/−/ND | − | mPSL, DSG | Graft loss |
Shimizu et al. [7] | 45/M | Living | Focal | 18 | −/−/ND | − | mPSL | Stable |
Yoshikawa et al. [8] | 37/M | Living | Diffuse | 36 | −/−/+ (DQ7) | − | mPSL, PEX, IVIG, Rit, DSG | Worsened |
Furuya et al. [9] | 33/M | Living | Focal | 12 | −/−/+ (DQ4, 6) | + | mPSL, PEX, IVIG, Rit | Stable |
Hasegawa et al. [10] | 30/M | Living | Diffuse | 18 | +/−/+ (DR52) | + | mPSL, IVIG, Rit, OKT3, DSG | Graft loss |
Katsuma et al. [11] | 56/M | Cadaver | Focal | 21 | +/−/+ (DR53) | + | mPSL, PEX, IVIG, Rit | Stable |
Our case | 47/M | Living | Focal | 3 | −/−/− | − | mPSL | improved |
Diffuse infiltration of PCAR was defined as score i3 in Banff classification or described as “Diffuse.” By contrast, less than i2 was described as “Focal.” ND: no data; VR: vascular rejection; RTx: renal transplantation; TG: transplant glomerulitis; DSA: donor-specific antibody; ABMR: antibody-mediated rejection; mPSL: methylprednisolone; PEX: plasma exchange; IVIG: intravenous immunoglobulin; Rit: Rituximab; OKT3: Muromonab-CD3; DSG: deoxyspergualin.